BIOLASE ANNOUNCES TRAINING INITIATIVE WITH THE EINSTEIN HEALTH NETWORK GENERAL DENTISTRY RESIDENCE PROGRAM

LAKE FOREST, Calif., July 13, 2022 /PRNewswire/ — BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced a pilot program with the Einstein Healthcare Network Residency in General Dentistry to train resident general dentists in the using Waterlase dental laser technology. The goal of the program is to provide residents with hands-on experience with dental lasers that are becoming the gold standard in dental care, allowing residents to immediately implement this technology when they walk into their future practice.

“BIOLASE is deeply committed to training the next generation of dental professionals,” said John Beaver, Chairman and CEO of BIOLASE. “It is important to us to live our mission to advance dentistry by empowering the next generation of Einstein residency program dentists. We are honored to be a part of not only residents’ future careers by arming them with innovative technologies, but also the future relationships they will establish with their patients by offering a less invasive and more positive experience.”

The Einstein Healthcare Network Residency in General Dentistry is one of the first hospital-based general dentistry programs approved by the American Dental Association. Residency is a 12-24 month program that admits eight residents each year, preparing graduates to practice, teach and conduct independent research.

“We are committed to actively seeking ways to help our residents feel fully equipped to enter the practice of general dentistry after leaving our program,” said Dr. Georges SoulimanProgram Director of the Postgraduate Department of General Dentistry at the Albert Einstein Center in philadelphia cream. “Partnering with BIOLASE to embed laser-assisted general dentistry training early in our residents’ careers allows us to tighten the learning curve, which can positively impact a practice’s bottom line and, ultimately delivering a better overall patient experience.”

Waterlase dental laser systems offer many benefits to general dentists, from faster procedures to new treatment options. Educating general dentists about the benefits of dental lasers is part of BIOLASE’s ongoing efforts to help improve patient experiences and outcomes. Learn more about the benefits of laser dentistry at biolase.com.

About Einstein Healthcare Network

Einstein Healthcare Network is a healthcare system with approximately 1,000 beds and more than 8,700 employees serving communities in philadelphia cream and Montgomery County, Pennsylvania. The network is made up of three acute care hospitals, including Einstein Medical Center Philadelphia, the largest independent academic medical center in the philadelphia cream the region trains more than 3,500 student health professionals each year with more than 450 residents and fellows in more than 35 accredited programs; Einstein Medical Center Elkins Park; and the Einstein Montgomery Medical Center. The network also includes MossRehab, consistently ranked by US News & World Report as one of the nation’s top rehabilitation hospitals; Willowcrest, named by US News & World Report as one of the best nursing homes for short-term rehabilitation care in philadelphia cream; ambulatory care centers; and a network of over 900 physicians and primary care specialists across the region. For more information, visit www.einstein.edu.

About BIOLASE

BIOLASE is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. BIOLASE products advance the practice of dentistry and medicine for patients and healthcare professionals. BIOLASE’s proprietary laser products incorporate approximately 301 patented and 32 patent-pending technologies designed to provide biologically and clinically superior performance with less pain and faster recovery times. BIOLASE’s innovative products offer advanced technology at competitive prices to deliver superior results for dentists and patients. BIOLASE’s main products are revolutionary dental laser systems that perform a wide range of dental procedures, including cosmetic and complex surgical applications. BIOLASE has sold over 43,300 laser systems to date in over 80 countries worldwide. The laser products under development address BIOLASE’s core dental market and other adjacent medical and consumer applications.

For updates and information on Waterlase iPlus®, Waterlase Express™ and laser dentistry, find BIOLASE online at www.biolase.com, Facebook at www.facebook.com/biolase, Twitter at www.twitter.com/biolaseincInstagram at www.instagram.com/waterlase_laserdentistry and LinkedIn at www.linkedin.com/company/biolase.

BIOLASE®, Waterlase® and Waterlase iPlus® are registered trademarks of BIOLASE, Inc.

Caution Regarding Forward-Looking Statements

This press release contains forward-looking statements, as that term is defined in the Private Litigation Reform Act of 1995, that involve significant risks and uncertainties. Forward-looking statements can be identified by the use of words such as “may”, “could”, “will”, “intend”, “should”, “could”, “may”, “would”, “will continue”, “expect”, “believe”, “anticipate”, “estimate”, “predict”, “prospect”, “potential”, “plan”, “seek” and similar expressions and variations or the negatives of these terms or other comparable terms Readers are cautioned not to place undue reliance on these forward-looking statements, which reflect BIOLASE’s current expectations and speak only as of the date of this release. Actual results may differ materially from BIOLASE’s current expectations based on a number of factors. These factors include, among others, the risks and uncertainties that are described in the “Risk Factors” section of BIOLASE’s annual report filed on Form 10-K filed with the Securities and Exchange Commission. Except as required by law, BIOLASE assumes no responsibility to revise or update any forward-looking statement.

For more information, please contact:

EVC Group LLC
Michel Polyviou /Todd Kehrli
(732) 933-2754
[email protected] / [email protected]

SOURCE BIOLASE, Inc.

Ryan H. Bowman